Key Presentations From the ASCO 2014 Genitourinary Cancer Symposium: Renal Cell Cancer
Dr. Bradley Somer of The West Clinic in Memphis, Tennessee, attended the ASCO Genitourinary Cancers Symposium in San Francisco, held January 30 through February 2, 2014. Here he talks about the presentations that he found most likely to impact clinical practice.
Renal Cell Cancer
Abstract 396 Cytoreductive nephrectomy (CN) in patients with synchronous metastases from renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC)
Take-Home Message: In renal cancer, data were presented from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) on the role of cytoreductive nephrectomy in patients with metastatic RCC. Essentially, the data suggested that, when there are more than three IMDC prognostic factors present (Karnofsky performance status < 80%; an interval < 1 year between diagnosis and treatment; anemia; thrombocytopenia; neutrophilia; and hypercalcemia), there is really no benefit to cytoreductive nephrectomy. However, the lower number of IMDC prognostic scores, the more likely the patient seems to benefit from cytoreductive nephrectomy.
Abstract 398 The International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) model as a prognostic tool in metastatic renal cell carcinoma (mRCC) patients previously treated with first-line targeted therapy (TT)
Take-Home Message: Additionally, a presentation was made validating the use of the IMDC criteria in metastatic RCC for first-line therapy with VEGF-TKIs and also as predictors of survival prior to initiating second-line therapy.
Click on any of these tags to subscribe to Topic Alerts. Once subscribed, you can get a single, daily email any time PracticeUpdate publishes content on the topics that interest you.
Visit your Preferences and Settings section to Manage All Topic Alerts
Additional Info
Disclosure statements are available on the authors' profiles: